drug
resist
costli
consequ
pathogen
evolut
major
concern
public
health
review
show
popul
genet
use
studi
evolut
drug
resist
also
drug
resist
evolut
inform
evolutionari
model
system
highlight
five
exampl
divers
organ
particular
focu
identifi
drug
resist
loci
malaria
parasit
plasmodium
falciparum
use
genom
signatur
select
sweep
ii
determin
role
epistasi
drug
resist
evolut
influenza
iii
quantifi
role
stand
genet
variat
evolut
drug
resist
hiv
iv
use
drug
resist
mutat
studi
clonal
interfer
dynam
tuberculosi
v
analys
popul
structur
core
accessori
genom
staphylococcu
aureu
understand
spread
methicillin
resist
throughout
review
discuss
use
sequenc
data
popul
genet
theori
studi
evolut
drug
resist
pathogen
evolut
major
public
health
concern
enorm
societ
consequ
around
world
pathogen
evolv
quickli
allow
jump
multipl
host
speci
human
eg
sar
coronaviru
ebola
viru
woolhous
et
al
becom
virul
evad
immun
pressur
within
human
eg
influenza
viru
grenfel
et
al
becom
resist
drug
use
combat
prevent
least
manag
drug
resist
pathogen
imper
understand
evolutionari
aspect
problem
howev
evolutionari
biologist
tradit
left
studi
drug
resist
medicin
epidemiolog
commun
read
huijben
chang
recent
year
interest
popul
genet
work
done
natur
popul
pathogen
featur
review
chang
least
part
driven
avail
genet
data
varieti
pathogen
new
crossdisciplinari
field
emerg
use
larg
amount
genet
data
new
theoret
advanc
world
popul
genet
work
directli
aim
find
way
prevent
drug
resist
evolut
spread
wherea
work
basic
natur
mostli
use
pathogen
model
system
learn
evolut
gener
best
case
learn
lesson
prevent
resist
gener
evolutionari
principl
simultan
aim
review
introduc
research
differ
field
new
excit
work
drug
resist
evolut
happen
intersect
popul
genet
medic
field
virolog
infecti
diseas
perhap
importantli
review
intend
advertis
strength
use
natur
pathogen
popul
studi
evolutionari
principl
well
strength
use
evolutionari
theori
better
understand
dynam
infecti
diseas
end
present
five
case
studi
intersect
evolutionari
theori
pathogen
drug
resist
five
exampl
chosen
meant
exhaust
way
exampl
showcas
evolutionari
question
context
differ
pathogen
uniqu
biolog
differ
genom
size
method
genet
exchang
reproduct
recombin
see
box
describ
follow
five
exampl
select
sweep
map
malaria
parasit
p
falciparum
resist
antimalari
drug
artemisinin
great
exampl
popul
genet
method
origin
develop
sexual
recombin
eukaryot
organ
human
could
appli
p
falciparum
experi
high
rate
sexual
recombin
map
drug
resist
mutat
p
falciparum
allow
research
track
preval
artemisinin
resist
worldwid
role
epistasi
oseltamivir
tamiflu
resist
influenza
evolut
spread
oseltamivir
resist
influenza
unexpect
even
though
causal
mutat
oseltamivir
resist
known
thought
costli
viral
fit
spread
wide
phylogenet
method
allow
research
discov
mutat
interact
resist
mutat
amelior
detriment
effect
allow
resist
mutat
spread
influenza
becom
model
help
research
understand
import
genet
interact
site
cours
evolut
potenti
predict
futur
evolut
import
stand
genet
variat
sgv
also
refer
minor
variant
treatment
failur
human
immunodefici
viru
hiv
drug
resist
mutat
well
known
hiv
evolut
drug
resist
happen
independ
differ
patient
make
possibl
determin
import
sgv
drug
resist
hiv
sever
studi
found
sgv
de
novo
mutat
contribut
drug
resist
hiv
clonal
interfer
dynam
mycobacterium
tuberculosi
drug
resist
mutat
also
well
known
tuberculosi
track
mutat
recent
studi
reveal
clonal
interfer
play
larg
role
evolutionari
dynam
within
patient
examin
dynam
offer
insight
multiplyresist
strain
emerg
also
provid
rare
look
natur
popul
evolv
without
recombin
popul
structur
analysi
core
accessori
genom
methicillinresist
staphylococcu
aureu
mrsa
staphylococcu
aureu
reproduc
clonal
yet
drug
resist
often
acquir
via
spread
mobil
genet
element
horizont
gene
transfer
gene
cassett
sccmec
confer
methicillin
resist
genealog
core
genom
mrsa
reveal
rel
lineag
spread
across
globe
phylogenet
analysi
sccmec
reveal
methicillin
resist
aris
local
scale
five
exampl
use
illustr
grow
avail
sequenc
data
facilit
applic
popul
genet
method
import
question
evolut
drug
resist
malaria
result
death
everi
year
mainli
caus
p
falciparum
past
year
sever
antimalari
drug
deploy
resist
drug
develop
repeatedli
current
frontlin
treatment
artemisininbas
combin
therapi
act
introduc
time
drug
fail
act
initi
effect
first
sign
resist
artemisinin
emerg
southeast
asia
resist
widespread
noedl
et
al
dondorp
et
al
dondorp
et
al
kyaw
et
al
ashley
et
al
better
track
global
spread
resist
antimalari
drug
understand
mechan
resist
develop
essenti
know
locat
p
falciparum
genom
confer
resist
review
popul
genet
method
use
identifi
kelch
gene
chromosom
confer
resist
artemisinina
locu
recent
gone
rel
unnot
whose
biolog
function
still
unknownand
experiment
method
use
confirm
causal
mutat
highlight
p
falciparum
review
pathogen
experi
strong
select
pressur
unlik
human
pathogen
eukaryot
organ
experi
high
rate
recombin
see
box
show
properti
p
falciparum
make
rel
straightforward
appli
standard
popul
genet
method
malaria
order
detect
select
site
great
success
even
though
method
often
design
eukaryot
model
organ
common
method
detect
select
sweep
recombin
eukaryot
includ
plasmodium
falciparum
select
sweep
adapt
mutat
rise
frequenc
popul
drag
link
genet
materi
haplotyp
background
high
frequenc
via
hitchhik
maynard
smith
haigh
kaplan
et
al
kim
stephan
result
pattern
low
genet
variat
high
linkag
disequilibrium
ld
high
haplotyp
homozygos
vicin
adapt
mutat
plasmodium
falciparum
experi
high
rate
recombin
cmmb
su
et
al
jiang
et
al
sever
statist
util
ld
haplotyp
homozygos
inform
identifi
select
sweep
includ
extend
haplotyp
homozygos
ehh
cross
popul
extend
haplotyp
homozygos
xpehh
well
ih
nsl
sabeti
et
al
sabeti
et
al
voight
et
al
ferreradmetlla
et
al
garud
et
al
ehh
xpehh
particularli
popular
success
detect
site
select
p
falciparum
ehh
measur
decay
tract
homozygos
radiat
away
snp
partial
frequenc
singl
popul
sabeti
et
al
howev
ehh
power
detect
select
sweep
gone
fixat
sabeti
et
al
contrast
xpehh
util
inform
two
popul
one
sweep
presum
occur
anoth
sweep
sabeti
et
al
xpehh
thu
power
detect
partial
complet
sweep
occur
one
two
popul
consid
addit
ldbase
statist
sever
site
frequenc
spectrum
sf
statist
treat
individu
polymorph
site
sampl
independ
one
anoth
statist
tajima
tajima
fay
wu
h
fay
wu
fay
et
al
sweepfind
nielsen
et
al
sensit
dip
neutral
divers
excess
low
high
frequenc
polymorph
sf
braverman
et
al
vitti
et
al
anoth
wide
use
sf
statist
f
st
lewontin
krakauer
compar
genom
pattern
two
popul
specif
f
st
measur
differ
averag
pairwis
divers
measur
randomli
sampl
individu
across
two
differ
popul
vs
within
singl
popul
thu
indic
posit
select
one
popul
diverg
extrem
divers
anoth
explain
review
f
st
success
use
conjunct
ehh
xpehh
detect
select
site
p
falciparum
across
multipl
popul
associ
test
ldbase
approach
often
use
identifi
drug
resist
loci
multipl
studi
system
associ
test
correl
phenotyp
allel
state
polymorph
sampl
singl
popul
anderson
et
al
case
p
falciparum
artemisinin
resist
character
slow
parasit
clearanc
rate
measur
rate
decay
parasit
densiti
blood
time
noedl
et
al
dondorp
et
al
therefor
phenotyp
use
studi
identifi
underli
mutat
confer
resist
artemisinin
associ
studi
result
mani
fals
posit
number
confound
factor
popul
substructur
related
individu
sampl
furthermor
associ
studi
comput
slow
larg
sampl
size
larg
number
polymorph
site
effici
mix
model
associ
emma
associ
techniqu
aim
address
factor
kang
et
al
use
varieti
method
sever
loci
confer
resist
older
antimalari
drug
mefloquin
chloroquin
sulfadoxinepyrimethamin
atovaquon
eg
gene
encod
chloroquin
resist
transport
multidrug
resist
protein
gtpcyclohydrolas
dihydroptero
synthetas
dihydrofol
reductas
cytochrom
b
identifi
wootton
et
al
nair
et
al
ferdig
et
al
sidhu
et
al
musset
et
al
vinayak
et
al
anderson
et
al
mita
et
al
close
examin
genom
signatur
immedi
surround
loci
reveal
pattern
reduc
divers
elev
linkag
disequilibrium
ld
presenc
long
haplotyp
high
frequenc
wootton
et
al
nair
et
al
roper
et
al
vinayak
et
al
associ
signatur
select
sweep
maynard
smith
haigh
kaplan
et
al
kim
stephan
distinct
genom
signatur
result
drug
resist
p
falciparum
suggest
novel
loci
confer
resist
artemisinin
discov
search
pattern
elev
ld
haplotyp
homozygos
box
discuss
popular
popul
genom
method
use
identifi
select
sweep
resist
loci
p
falciparum
includ
ld
statist
xpehh
sabeti
et
al
sf
statist
use
corrobor
find
made
ld
statist
f
st
lewontin
krakauer
genomewid
associ
studi
three
recent
studi
cheeseman
et
al
takalaharrison
et
al
miotto
et
al
examin
pattern
ld
haplotyp
homozygos
p
falciparum
genom
identifi
region
chromosom
associ
artemisinin
resist
locu
later
character
locu
ariey
et
al
three
studi
benefit
greatli
deep
sampl
p
falciparum
multipl
popul
display
artemisinin
drug
resist
phenotyp
slow
parasit
clearanc
rate
other
noedl
et
al
dondorp
et
al
data
allow
author
contrast
genom
pattern
strain
geograph
locat
display
slow
parasit
clearanc
rate
phenotyp
vs
first
major
studi
cheeseman
et
al
examin
genom
data
sampl
three
popul
lao
thailand
cambodia
resist
observ
thailand
cambodia
cheeseman
et
al
data
set
offer
opportun
contrast
thai
cambodia
sampl
lao
discov
put
loci
confer
resist
artemisinin
cheeseman
et
al
util
twostep
approach
identifi
genom
region
underli
resist
artemisinin
first
author
use
xpehh
sabeti
et
al
f
st
lewontin
krakauer
statist
identifi
region
signific
candid
select
least
one
popul
statist
particularli
appropri
multipopul
data
set
design
contrast
genom
signatur
two
popul
box
cheeseman
et
al
found
kang
et
al
test
associ
snp
data
set
parasit
clearanc
phenotyp
therebi
identifi
four
snp
significantli
associ
includ
two
chromosom
conjunct
associ
test
takalaharrison
et
al
appli
xpehh
sabeti
et
al
f
st
lewontin
krakauer
cambodia
popul
use
thai
bangladeshi
popul
comparison
popul
author
found
polymorph
chromosom
previous
identifi
emma
test
also
signific
xpehh
f
st
valu
takalaharrison
et
al
use
haploview
barrett
et
al
visual
extend
haplotyp
homozygos
region
miotto
et
al
examin
locat
west
africa
southeast
asia
found
except
high
amount
popul
substructur
within
cambodia
upon
closer
examin
author
found
three
four
cluster
p
falciparum
found
western
cambodia
show
slow
parasit
clearanc
rate
slow
decay
ld
loss
haplotyp
divers
fourth
cluster
preval
northeastern
cambodia
show
characterist
lead
author
conclud
western
cambodia
harbour
least
three
distinct
popul
artemisininresist
p
falciparum
particular
one
subpopul
resist
strain
p
falciparum
show
singl
haplotyp
extend
across
half
chromosom
corrobor
evid
cheeseman
et
al
takalaharrison
et
al
locu
implic
resist
artemisinin
cheeseman
et
al
takalaharrison
et
al
miotto
et
al
abl
local
put
locu
chromosom
strongli
associ
slow
parasit
clearanc
phenotyp
recent
ariey
et
al
abl
identifi
caus
mutat
high
confid
ariey
et
al
use
vitro
drug
select
techniqu
subject
parasit
line
high
dose
artemisinin
year
compar
sequenc
data
select
line
clonal
popul
experienc
select
author
identifi
eight
mutat
seven
gene
present
artemisinin
treatment
group
absent
control
group
ariey
et
al
narrow
list
candid
conclud
mutat
appear
kelch
gene
chromosom
appear
time
artemisinin
resist
develop
treatment
group
determin
whether
concord
presenc
mutat
kelch
gene
artemisininresist
parasit
cambodia
ariey
et
al
sequenc
locu
mutat
present
parasit
sampl
patient
show
drugresist
phenotyp
patient
differ
geograph
locat
cambodia
found
mutat
kelch
gene
strongli
associ
slow
clearanc
phenotyp
observ
locat
malaria
preval
extend
analysi
ariey
et
al
identifi
mutat
kelch
gene
significantli
associ
artemisinin
resist
sever
followup
studi
confirm
find
ariey
et
al
ashley
et
al
examin
geograph
extent
resist
track
preval
mutat
kelch
gene
see
fig
author
found
sever
singl
point
mutat
kelch
significantli
associ
slow
parasit
clearanc
rate
recent
work
cheeseman
et
al
miotto
et
al
takalaharrison
et
al
tun
et
al
also
precis
map
origin
extent
mutat
associ
artemisinin
resist
see
fig
ghorbal
et
al
use
system
introduc
mutat
implic
artemisinin
resist
ariey
et
al
kelch
produc
slow
parasit
clearanc
phenotyp
demonstr
first
direct
link
mutant
kelch
characterist
phenotyp
work
expand
upon
straimer
et
al
confirm
role
multipl
mutat
addit
genet
factor
confer
artemisinin
resist
five
exampl
review
studi
exampl
use
classic
statist
method
find
associ
kelch
gene
artimisinin
resist
p
falciparum
perhap
familiar
popul
geneticist
eukaryot
pathogen
high
rate
recombin
sequenc
analysi
p
falciparum
genom
amen
tradit
genom
scan
approach
clever
stratif
sampl
gave
addit
power
genom
scan
combin
novel
experiment
method
research
abl
find
locu
recent
strong
select
respons
evolut
resist
artimisinin
identif
kelch
gene
popul
genet
method
offer
clear
exampl
standard
methodolog
identifi
select
sweep
power
identifi
causal
locu
given
p
falciparum
manipul
experiment
confirm
comput
predict
organ
attract
choic
futur
studi
drug
resist
especi
sinc
malaria
continu
costli
diseas
new
drugresist
loci
may
unknown
annual
influenza
epidem
estim
result
million
case
sever
ill
death
worldwid
subtyp
influenza
type
viru
name
accord
two
surfac
protein
allow
influenza
viru
bind
releas
host
cell
hemagglutinin
ha
neuraminidas
na
exampl
design
particular
subtyp
influenza
respons
swine
flu
epidem
two
surfac
protein
hemagglutinin
neuraminidas
primari
antigen
target
immun
system
also
potenti
target
pharmaceut
intervent
one
common
influenza
drug
oseltamivir
market
trade
name
tamiflu
oseltamivir
work
inhibit
influenza
neuraminidas
surfac
protein
protein
cleav
sialic
acid
receptor
host
cell
allow
replic
viru
spread
uninfect
cell
moscona
resist
oseltamivir
influenza
confer
singl
histidinetotyrosin
amino
acid
chang
amino
acid
posit
neuraminidas
protein
note
amino
acid
often
refer
amino
acid
posit
convent
follow
mutat
known
laboratori
studi
research
predict
fit
cost
would
prevent
spread
wide
howev
oseltamivir
resist
due
mutat
document
extens
follow
flu
season
global
surveil
indic
increas
preval
influenza
virus
acquir
resist
moscona
combin
phylogenet
eleg
laboratori
studi
led
discoveri
two
permiss
mutat
mitig
cost
mutat
thu
show
import
epistasi
influenza
evolut
studi
evolut
oseltamivir
resist
reli
heavili
phylogenet
method
taught
us
import
epistasi
turn
crucial
import
make
predict
influenza
evolut
interact
among
site
genom
give
rise
phenomenon
call
epistasi
effect
one
mutat
site
depend
presenc
absenc
mutat
site
epistat
interact
exist
ensur
fit
effect
drug
resist
mutat
depend
genet
background
emerg
epistasi
drug
resist
evolut
character
sever
vitro
studi
includ
case
five
interact
mutat
involv
cefotaxim
resist
escherichia
coli
produc
predict
mutat
order
weinreich
et
al
hundr
interact
mutat
determin
viral
fit
antiretrovir
resist
hiv
hinkley
et
al
case
oseltamivir
resist
mutat
shown
detriment
effect
viral
fit
first
identifi
laboratori
ive
et
al
abe
et
al
herloch
et
al
led
research
believ
virus
carri
unlik
clinic
consequ
ive
et
al
resist
strain
subsequ
reach
global
frequenc
nearli
flu
season
bloom
other
show
mutat
reduc
amount
fold
neuramindas
reach
host
cell
surfac
therebi
reduc
viru
fit
hypothes
secondari
mutat
site
influenza
genom
may
act
amelior
deleteri
effect
mutat
permit
reach
high
global
frequenc
bloom
et
al
bloom
colleagu
took
sequenc
creat
phylogenet
tree
found
five
nonsynonym
mutat
separ
strain
common
strain
found
strongli
neg
fit
effect
ad
mutat
one
one
strain
found
two
five
mutat
strong
effect
amount
neuraminidas
cell
surfac
virus
two
mutat
longer
reduc
fit
viru
absenc
oseltamivir
creat
triplemut
viru
mutat
fit
compar
wild
type
presenc
oseltamivir
triplemut
viru
much
higher
fit
wild
type
bloom
et
al
phylogeni
statu
three
mutat
shown
fig
subsequ
studi
also
identifi
potenti
epistat
interact
mutat
hemagglutinin
neuraminidas
impact
viral
fit
may
influenc
spread
oseltamivir
resist
hensley
et
al
gint
et
al
behera
et
al
taken
togeth
result
suggest
epistasi
profound
impact
evolut
resist
oseltamivir
allow
resist
mutat
spread
global
popul
work
also
provid
cautionari
evid
clinic
assess
drug
resist
mutat
secondari
mutat
interact
epistat
drug
resist
mutat
import
factor
need
incorpor
make
predict
epidemiolog
consequ
drug
resist
mutat
know
even
deleteri
drug
resist
mutat
spread
emerg
permiss
background
tell
us
pay
close
attent
identifi
monitor
potenti
epistat
interact
virolog
surveil
extent
epistasi
gener
featur
adapt
evolut
theoret
empir
work
predict
adapt
may
enrich
epistat
interact
draghi
et
al
draghi
plotkin
gong
et
al
rajon
masel
szendro
et
al
gong
bloom
mean
epistasi
like
play
gener
role
adapt
evolut
limit
specif
case
studi
also
mean
research
interest
adapt
need
model
system
test
theori
regard
epistasi
influenza
resist
evolut
form
model
test
popul
genet
predict
regard
role
epistasi
adapt
evolut
oseltamivir
resist
evolut
provid
first
evalu
methodolog
potenti
predict
site
within
protein
interact
one
anoth
base
sequenc
data
phylogenet
tree
bloom
colleagu
initi
predict
mutat
potenti
candid
posit
epistat
interact
use
phylogenet
method
bloom
glassman
infer
stabil
effect
mutat
show
inde
restor
surfac
express
wild
type
level
absenc
oseltamivir
bloom
et
al
meanwhil
kryazhimskiy
et
al
examin
hemagglutinin
neuraminidas
sequenc
multipl
influenza
strain
success
predict
known
epistat
interact
collin
et
al
anoth
mutat
see
fig
addit
mutat
identifi
bloom
et
al
methodolog
base
statist
rank
cooccurr
specif
amino
acid
substitut
within
phylogeni
predict
evolut
influenza
intrigu
prospect
evolutionari
geneticist
briefli
discuss
discuss
studi
shown
phylogenet
method
affirm
theoret
predict
regard
pattern
epistasi
also
predict
epistat
interact
may
clinic
import
also
establish
connect
protein
phylogeni
fit
may
prove
use
futur
work
popul
genet
infecti
diseas
hiv
drug
resist
challeng
sinc
introduct
hiv
treatment
hiv
adapt
rapidli
due
high
mutat
rate
fast
gener
time
larg
popul
size
coffin
although
drug
resist
hiv
becom
less
preval
treatment
improv
lee
et
al
feder
et
al
fundament
question
clinician
popul
geneticist
remain
exactli
drugresist
mutat
drm
origin
patient
may
preexist
drug
resist
mutat
prior
receiv
drug
therapi
although
preexist
mutat
also
known
sgv
may
offer
select
advantag
could
fact
deleteri
onset
treatment
therapi
begin
quickli
rise
high
frequenc
hiv
popul
caus
treatment
failur
pen
howev
hiv
also
acquir
drug
resist
mutat
de
novo
onset
therapi
clinic
extent
drug
resist
mutat
aris
sgv
de
novo
mutat
inform
treatment
approach
sgv
critic
import
establish
drug
resist
effort
focus
identifi
potenti
drug
resist
mutat
pretreat
hiv
popul
determin
appropri
regimen
howev
resist
occur
de
novo
start
treatment
patient
adher
drug
penetr
dosag
clinic
focu
end
import
understand
whether
drug
resist
mutat
present
treatment
onset
identifi
patient
sampl
assess
ultim
contribut
sgv
treatment
failur
popul
genet
perspect
drug
resist
evolut
hiv
allow
us
understand
role
sgv
adapt
gener
first
everi
infect
person
independ
evolutionari
replic
transmit
drug
resist
rel
rare
around
untreat
patient
transmit
drug
resist
mutat
depend
region
world
although
number
lower
consid
drug
resist
specif
treatment
therefor
drug
resist
emerg
independ
within
patient
suffici
follow
singl
patient
time
chart
evolut
hiv
popul
contrast
monitor
acquisit
drug
resist
mutat
across
multipl
patient
transmiss
chain
second
mutat
confer
drug
resist
well
catalogu
bennett
et
al
wens
et
al
allow
us
quantifi
frequenc
prior
treatment
use
allelespecif
pcr
aspcr
final
adapt
rapid
allow
us
observ
evolut
drug
resist
happen
hivinfect
person
start
treatment
blood
sampl
taken
sequenc
viru
see
schutten
overview
genotyp
assay
sanger
sequenc
hiv
start
treatment
standard
clinic
practic
nextgener
sequenc
simen
et
al
et
al
sequenc
proteas
revers
transcriptas
integras
gene
use
determin
whether
drug
resist
mutat
present
high
frequenc
result
help
clinician
patient
choos
combin
drug
start
treatment
hirsch
et
al
major
viral
popul
patient
carri
resist
mutat
inform
use
choos
drug
regimen
work
specif
viru
howev
drug
resist
mutat
low
popul
frequenc
less
detect
standard
sequenc
protocol
simen
et
al
import
question
therefor
whether
lowfrequ
sgv
present
patient
whether
allow
viral
popul
adapt
evolv
drug
resist
import
studi
pared
et
al
use
aspcr
determin
whether
drug
resist
mutat
alreadi
present
minor
variant
viral
popul
patient
patient
origin
took
part
clinic
trial
blood
sampl
start
treatment
treatment
failur
applic
store
treatment
failur
defin
viru
detect
blood
level
higher
expect
given
patient
treatment
author
focus
two
import
resist
mutat
revers
transcriptas
gene
patient
treat
combin
revers
transcriptas
inhibitor
patient
found
either
alreadi
present
minor
variant
mostli
around
frequenc
could
detect
mutat
patient
patient
minor
variant
treatment
fail
success
patient
without
minor
variant
treatment
fail
success
altogeth
treatment
fail
patient
consid
patient
without
detect
sgv
treatment
fail
patient
mean
patient
failur
attribut
presenc
minor
variant
see
fig
estim
pared
et
al
treatment
failur
come
sgv
may
underestim
author
look
presenc
two
drug
resist
mutat
may
detect
variant
case
howev
two
mutat
import
treatment
look
result
fairli
similar
differ
estim
describ
less
direct
method
studi
role
sgv
evolut
hiv
drug
resist
develop
one
us
pen
reanalys
data
previou
studi
margot
et
al
look
excess
adapt
earli
treatment
found
studi
interest
resist
evolut
happen
constant
rate
second
third
year
treatment
year
viru
acquir
resist
patient
previous
viru
without
drug
resist
constant
rate
evolut
drug
resist
also
observ
sever
trial
eg
uk
collabor
group
hiv
drug
resist
uk
chic
studi
group
other
year
treatment
sgv
present
treatment
probabl
play
role
like
reflect
evolut
resist
de
novo
mutat
first
year
treatment
expect
new
mutat
sgv
contribut
evolut
resist
resist
evolv
patient
viral
popul
suggest
sgv
play
role
margot
et
al
patient
total
first
year
treatment
expect
number
peopl
resist
year
rate
seen
year
year
realiti
peopl
resist
expect
thirtysix
see
fig
estim
sgv
lead
resist
patient
one
may
note
total
number
fail
patient
much
higher
pared
et
al
may
stricter
criterion
treatment
success
copi
pared
et
al
vs
copi
margot
et
al
also
patient
similar
treatment
pared
studi
tdfefv
margot
studi
light
differ
overal
rate
evolut
two
studi
perhap
surpris
see
estim
rate
evolut
sgv
similar
pen
use
third
data
set
estim
rate
evolut
resist
due
sgvbase
trial
long
treatment
interrupt
patient
danel
et
al
estim
suggest
estim
fairli
robust
pen
adapt
sgv
discuss
extens
literatur
howev
rel
studi
attempt
quantifi
rel
import
mode
adapt
altogeth
result
studi
hiv
suggest
sgv
play
import
quantit
predict
role
treatment
failur
particular
diseas
sgv
may
also
play
larg
role
treatment
outcom
diseas
caus
pathogen
other
cancer
bozic
et
al
nextgener
sequenc
use
determin
whether
drugresist
sgv
exist
patient
prior
treatment
thu
inform
clinic
decis
individu
patient
apart
clinic
relev
particular
exampl
hiv
drug
resist
evolut
also
wellsuit
valid
evolutionari
theori
regard
adapt
sgv
orr
betancourt
hermisson
pen
barrett
schluter
mycobacterium
tuberculosi
caus
agent
tuberculosi
tb
nonrecombin
bacterium
believ
reproduc
entir
clonal
although
see
namouchi
et
al
mycobacterium
tuberculosi
latent
infect
approxim
onethird
world
popul
tuberculosi
caus
million
death
vast
major
death
occur
lowor
middlewealth
countri
although
tuberculosi
often
effect
treat
combin
therapi
antibiot
drug
resist
common
nearli
known
drug
multipli
drugresist
extens
drugresist
strain
particularli
difficult
treat
requir
longer
cours
expens
medic
therefor
much
work
done
categor
genom
locat
probabl
mechan
drug
resist
mutat
mani
mutat
identifi
confer
larg
degre
drug
resist
within
patient
drug
resist
mutat
found
collect
tuberculosi
sampl
assay
growth
media
contain
differ
antibiot
identifi
associ
mutat
resist
profil
comprehens
list
drug
resist
mutat
found
tuberculosi
drug
resist
databas
sandgren
et
al
drug
resist
mutat
variou
effect
size
nine
drug
record
within
differ
gene
despit
appar
adapt
tuberculosi
divers
intrapati
popul
histor
consid
low
sreevatsan
et
al
musser
et
al
recent
studi
found
consider
divers
exist
within
tuberculosi
popul
alhajoj
et
al
navarro
et
al
sun
et
al
eldholm
et
al
combin
new
sequenc
data
knowledg
welldocu
drug
resist
mutat
tuberculosi
test
theoret
understand
clonal
evolut
proce
arriv
complet
pictur
tuberculosi
drug
resist
emerg
within
patient
recombin
thought
evolutionarili
adapt
allow
differ
adapt
mutat
resid
differ
genet
background
popul
appear
togeth
fisher
muller
felsenstein
addit
unlink
posit
select
trait
deleteri
passeng
mutat
mitig
effect
link
select
hill
robertson
birki
walsh
good
desai
popul
recombin
mutat
remain
genet
background
origin
occur
therefor
multipl
posit
select
trait
enter
popul
simultan
differ
background
trait
recombin
augment
instead
must
compet
rise
frequenc
popul
muller
process
known
clonal
interfer
gerrish
lenski
clonal
interfer
extens
model
rouzin
et
al
desai
fisher
park
krug
marten
hallatschek
neher
investig
laboratori
experi
miral
et
al
pepin
wichman
kvitek
sherlock
lang
et
al
system
exist
allow
us
test
predict
natur
popul
global
influenza
seem
evolv
clonal
across
year
strelkowa
intrahost
popul
nonrecombin
bacteria
allow
mani
semiindepend
evolutionari
trajectori
compar
much
shorter
time
scale
although
evid
hiv
experi
clonal
interfer
within
patient
recombin
complic
studi
pandit
de
boer
also
strong
interest
clonal
evolut
cancer
sampl
differ
time
point
often
much
harder
cancer
tuberculosi
hiv
make
cancer
studi
system
difficult
walter
et
al
intrahost
evolut
tuberculosi
provid
fairli
straightforward
way
examin
clonal
interfer
vivo
understand
extent
slow
evolutionari
process
recombin
allel
frequenc
pool
resequenc
case
reconstruct
haplotyp
see
larg
genom
size
mb
welldocu
drug
resist
mutat
long
time
cours
infect
mean
pattern
divers
track
time
although
previou
studi
shown
presenc
compet
clonal
lineag
tuberculosi
popul
patient
use
neutral
marker
alhajoj
et
al
navarro
et
al
use
understand
drug
resist
mutat
better
understand
evolutionari
dynam
withinhost
popul
among
patient
infect
drugsensit
strain
tuberculosi
drug
resist
evolv
within
patient
treatment
track
frequenc
drug
resist
mutat
time
singl
patient
observ
clonal
interfer
lineag
carri
benefici
mutat
real
time
sun
et
al
conduct
first
analysi
kind
track
drug
resist
allel
frequenc
three
patient
across
least
two
time
point
first
patient
entir
free
drug
resist
mutat
onset
treatment
second
time
point
sampl
four
segreg
drug
resist
mutat
final
time
point
sampl
singl
drug
resist
mutat
divid
among
drugresist
strain
includ
contain
drug
resist
mutat
present
second
time
point
suggest
tuberculosi
rapidli
acquir
resist
mutat
differ
drugresist
strain
compet
due
lack
recombin
second
patient
enter
studi
tuberculosi
popul
fix
certain
drug
resist
mutat
rpob
remain
sensit
antibiot
rifampicin
eighteen
month
later
patient
popul
whose
genet
composit
domin
differ
drug
resist
mutat
rpob
resist
rifampicin
suggest
success
sweep
altern
drug
resist
mutat
lead
multidrugresist
strain
eldholm
et
al
perform
similar
studi
much
greater
sequenc
depth
singl
patient
follow
month
extens
drug
resist
acquir
pathogen
patient
start
standard
antibiot
regimen
pyrazinamid
rifampicin
isoniazid
given
increasingli
uncommon
drug
tuberculosi
popul
acquir
drug
resist
mutat
dynam
clonal
interfer
shown
fig
base
data
eldholm
et
al
allel
frequenc
measur
sever
time
point
allel
similar
frequenc
trajectori
assum
background
clone
therefor
clonal
frequenc
chang
infer
across
time
eldholm
et
al
identifi
drug
resist
mutat
reach
frequenc
seven
ultim
fix
shown
green
suggest
clonal
interfer
may
purg
strongli
select
drug
resist
mutat
even
reach
high
frequenc
shown
blue
knowledg
posit
select
drug
resist
mutat
also
allow
us
understand
dynam
cooccur
hitchhik
mutat
alreadi
background
drug
resist
mutat
aros
eldholm
et
al
found
mutat
directli
associ
drug
resist
also
fix
popul
week
sampl
mutat
may
neutral
compensatori
posit
select
adapt
unrel
drug
also
possibl
slightli
deleteri
rose
frequenc
due
linkag
benefici
mutat
eldholm
et
al
may
note
case
drug
resist
mutat
ad
haplotyp
one
one
suggest
individu
mutat
lead
increas
fit
troubl
part
rational
behind
use
multipl
drug
time
make
much
harder
pathogen
evolv
resist
need
acquir
multipl
mutat
time
suggest
imperfect
drug
penetr
may
explain
evolut
resist
tuberculosi
despit
multidrug
therapi
lipsitch
levin
morenogamez
et
al
studi
clonal
interfer
thu
far
larg
investig
within
experiment
theoret
model
uniqu
applic
studi
clonal
dynam
natur
popul
human
pathogen
tuberculosi
use
presenc
drug
resist
mutat
posit
control
strong
direct
select
abl
better
understand
evolutionari
dynam
clonal
evolv
pathogen
popul
tuberculosi
although
current
detail
data
wellstudi
patient
includ
deep
coverag
entir
genom
across
multipl
time
point
appear
case
clonal
interfer
tuberculosi
popul
occur
way
similar
seen
laboratori
experi
knowledg
hundr
drug
resist
mutat
avail
afford
wholegenom
sequenc
expect
see
mani
studi
withinhost
dynam
tuberculosi
near
futur
especi
look
forward
studi
popul
genet
use
understand
genet
pattern
associ
divers
treatment
outcom
grow
need
address
drug
resist
within
bacteri
speci
exhibit
horizont
gene
transfer
hgt
see
box
share
genet
materi
cell
resist
antibiot
increasingli
report
mani
bacteri
speci
hgt
includ
aureu
helicobact
pylori
salmonella
enterica
e
coli
mani
other
bacteri
speci
primarili
reproduc
clonal
pass
current
genom
vertic
next
gener
speci
hgt
also
genet
element
pass
individu
within
current
gener
recombin
genom
hgt
move
gene
set
gene
even
chromosom
cell
even
distantli
relat
speci
nelson
et
al
keel
palmer
syvanen
meric
et
al
make
defin
bacteri
speci
difficult
let
alon
track
spread
drug
resist
bacteria
circular
chromosom
typic
mb
size
copi
per
cell
gener
contain
core
essenti
genom
typic
code
fundament
function
like
dna
repair
replic
cell
structur
shape
metabol
function
mani
speci
bacteria
addit
accessori
satellit
genom
typic
size
core
genom
present
main
circular
chromosom
extrachromosom
element
plasmid
core
genom
usual
defin
set
genet
region
present
within
member
speci
accessori
genom
vari
individu
strain
cell
accessori
genom
whether
main
chromosom
includ
chromosom
cassett
bacteriophag
pathogen
island
genom
island
transposon
lindsay
holden
accessori
genom
sometim
call
dispens
requir
surviv
optim
environ
howev
accessori
genom
encod
inform
essenti
bacterium
surviv
environ
bacteria
evolv
elabor
fascin
method
share
accessori
gene
cell
amabilecueva
stoke
gill
share
genet
inform
cell
call
horizont
gene
transfer
hgt
bacteria
asexu
typic
defin
clonal
hgt
distinct
sex
alter
genom
recipi
new
mutat
gener
novel
genet
variat
within
popul
bacteria
hgt
occur
within
across
speci
even
case
transfer
across
kingdom
keel
palmer
actual
method
transfer
dna
cell
membran
includ
transform
transduct
conjug
transform
uptak
nake
dna
cell
gener
mediat
membran
protein
dna
specif
method
restrict
speci
evolv
uptak
dna
transduct
transfer
dna
mediat
phage
bacteriophag
virus
infect
replic
within
bacterium
thu
restrict
host
phage
capabl
infect
two
type
gener
transduct
random
bacteri
dna
incorpor
phage
dna
special
transduct
incorpor
limit
specif
set
bacteri
gene
perhap
common
method
hgt
conjug
requir
celltocel
contact
one
famou
method
conjug
e
coli
f
conjug
plasmid
code
cellular
structur
bring
cell
contact
call
pili
well
machineri
inject
dna
recipi
cell
genet
materi
transfer
via
hgt
recombin
onto
main
bacteri
chromosom
onto
extrachromosom
element
often
cassett
gene
evolv
togeth
spread
bacteri
popul
includ
mani
case
drug
resist
amabilecueva
stoke
gill
one
use
framework
understand
spread
drug
resist
speci
hgt
concept
select
sweep
gener
select
sweep
new
adapt
mutat
aris
spread
popul
caus
correspond
reduct
genet
divers
around
adapt
site
maynard
smith
haigh
clonal
popul
eg
popul
tuberculosi
select
sweep
lead
remov
entir
lineag
strong
genomewid
reduct
divers
contrast
recombin
popul
eg
popul
p
falciparum
extent
reduct
divers
invers
proport
ratio
recombin
select
rs
greatest
reduct
divers
occur
recombin
r
weak
select
strong
kaplan
et
al
select
sweep
organ
exhibit
hgt
best
understood
distinguish
genespecif
genomewid
select
sweep
shapiro
polz
genespecif
select
sweep
occur
adapt
mutat
gene
transmit
across
popul
faster
via
hgt
clonal
expans
mean
adapt
mutat
spread
independ
rest
genom
perhap
familiarli
genomewid
select
sweep
occur
adapt
mutat
spread
via
clonal
expans
genom
first
acquir
adapt
mutat
anoth
way
frame
genespecif
genomewid
select
sweep
think
ratio
recombin
mediat
via
hgt
select
rs
impact
genet
variat
genom
rs
genespecif
select
sweep
like
occur
littl
impact
genomewid
divers
rs
genomewid
select
sweep
like
genom
divers
strongli
reduc
thu
far
appear
mani
adapt
event
microbi
speci
hgt
may
fall
rs
regim
lead
genespecif
sweep
shapiro
polz
although
data
need
exampl
look
high
rs
ratio
may
partial
explain
slow
genomewid
sweep
due
clonal
interfer
perhap
select
lowfrequ
genotyp
shapiro
polz
nevertheless
use
frame
evolut
bacteri
speci
hgt
context
genomewid
genespecif
sweep
tradit
framework
studi
evolut
bacteri
genom
hgt
studi
evolut
within
core
genom
defin
gene
region
share
isol
within
speci
vs
accessori
genom
genet
materi
share
isol
speci
see
box
use
exampl
aureu
accessori
element
sccmec
explor
evolut
drug
resist
within
bacteri
speci
capabl
horizont
gene
transfer
note
sccmec
recombin
onto
circular
chromosom
gene
cassett
see
box
chosen
consid
mrsa
major
emerg
health
threat
also
instruct
exampl
phylogenet
relationship
global
isol
reveal
differ
evolutionari
histori
depend
whether
core
genom
accessori
genet
element
consid
staphylococcu
aureu
human
commens
known
caus
danger
skin
blood
stream
hospitalassoci
infect
well
abil
becom
resist
major
antibiot
lowi
stryjewski
corey
addit
methicillin
resist
first
emerg
also
grow
number
case
resist
antibiot
includ
vancomycin
quinolon
aminoglycosid
streptogramin
oxazolidinon
rifamycin
lowi
stryjewski
corey
mrsa
particularli
deadli
exampl
mortal
rate
patient
mrsa
bloodstream
infect
report
de
kraker
et
al
usa
infect
death
per
year
caus
mrsa
stockman
drug
resist
aris
via
new
mutat
within
genom
singl
clone
strahilevitz
hooper
howden
et
al
via
horizont
gene
transfer
clone
coomb
et
al
even
via
horizont
gene
transfer
anoth
bacteri
speci
hanssen
ericson
sollid
bloemenda
et
al
malachowa
deleo
smyth
et
al
staphylococcu
aureu
strain
acquir
methicillin
resist
via
mobil
genet
element
sccmec
like
via
transduct
defin
box
maslanova
et
al
integr
cassett
gene
bacterium
chromosom
genom
aureu
mbp
total
mbp
compos
core
genom
mbp
compos
accessori
genom
common
method
analys
genom
aureu
isol
multilocu
sequenc
type
mlst
standard
set
housekeep
gene
core
genom
sequenc
categor
allel
type
allow
placement
isol
defin
clonal
complex
enright
day
enright
et
al
maiden
et
al
mlst
histor
appli
core
genom
reveal
aureu
highli
clonal
speci
rel
recombin
event
core
genom
robinson
enright
mlst
appli
intern
collect
isol
appear
small
number
clonal
lineag
respons
infect
exampl
oliveira
et
al
appli
mlst
mrsa
isol
hospit
across
europ
south
america
usa
found
five
clone
caus
infect
oliveira
et
al
find
emerg
thought
methicillin
resist
like
spread
across
popul
aureu
rel
clone
acquir
sccmec
clonal
expand
ie
genomewid
sweep
kreiswirth
et
al
et
al
feil
enright
howev
closer
analysi
popul
structur
aureu
accessori
genom
reveal
differ
stori
first
decad
mrsa
outbreak
found
strain
caus
hospitalassoci
hamrsa
vs
communityassoci
camrsa
infect
display
distinct
clinic
genet
differ
differ
may
erod
address
later
hamrsa
tend
resist
wider
array
antibiot
often
caus
blood
stream
hospitalrel
infect
individu
addit
medic
condit
camrsa
tend
virul
caus
virul
gene
also
transmit
via
hgt
often
caus
skin
infect
otherwis
healthi
individu
david
daum
chua
et
al
clinic
differ
partli
mediat
mobil
genet
element
call
sccmec
chromosom
gene
cassett
confer
resist
methicillin
also
confer
resist
antibiot
katayama
et
al
hanssen
ericson
sollid
interestingli
genet
chang
within
gene
cassett
track
success
epidem
wave
mrsa
katayama
et
al
chamber
deleo
extens
work
done
investig
sourc
spread
mobil
element
phylogenet
inform
sequenc
adapt
factor
right
sccmec
current
classifi
type
subtyp
use
mutat
orient
segment
within
cassett
et
al
iwgscc
number
studi
show
popul
structur
aureu
differ
hamrsa
camrsa
strain
david
daum
mediavilla
et
al
stryjewski
corey
hamrsa
camrsa
strain
thought
aris
methicillinsensit
clone
newli
acquir
sccmec
cassett
sourc
popul
like
staphylococcu
speci
epidermidi
wu
et
al
hanssen
et
al
hanssen
et
al
meric
et
al
found
hamrsa
strain
tend
carri
longer
sccmec
type
ii
iii
element
clonal
background
wherea
camrsa
strain
tend
carri
shorter
sccmec
type
iv
v
element
divers
clonal
background
enright
et
al
robinson
enright
david
daum
coomb
et
al
exampl
earli
hamrsa
pandem
could
rel
neatli
classifi
five
clonal
complex
musser
kapur
fitzgerald
et
al
enright
et
al
robinson
enright
contrast
research
began
analys
strain
respons
emerg
camrsa
health
threat
found
strain
display
divers
stronger
associ
clonal
type
geograph
locat
chua
et
al
david
daum
coomb
et
al
sccmec
type
iv
element
alon
found
enter
least
nine
differ
clonal
complex
aureu
lina
et
al
clinic
genet
differ
hospitalassoci
ha
communityassoci
ca
mrsa
erod
modern
pandem
mainli
due
emerg
camrsa
strain
seed
increas
number
hospit
outbreak
chamber
deleo
david
daum
mediavilla
et
al
hsu
et
al
studi
mrsa
infect
mrsa
infect
citi
san
francisco
california
found
mrsa
infect
acquir
commun
liu
et
al
unit
state
current
predomin
camrsa
clone
call
typic
contain
sccmec
type
iv
respons
vast
major
communityassoci
infect
addit
caus
hospit
outbreak
seybold
et
al
chamber
deleo
mathemat
model
predict
camrsa
strain
eventu
replac
strain
tradit
categor
hamrsa
render
communityassoci
hospitalassoci
categori
far
less
use
dagata
et
al
success
camrsa
strain
potenti
mediat
arriv
sccmec
type
iv
cassett
may
particularli
suit
recurr
horizont
transfer
confer
faster
growth
rate
littl
fit
cost
okuma
et
al
diep
et
al
chamber
deleo
mediavilla
et
al
clinic
genet
differ
caand
hamrsa
strain
erod
modern
pandem
emphasi
differ
within
recent
literatur
instead
attent
move
toward
leverag
new
sequenc
technolog
maiden
et
al
achiev
higher
resolut
global
pattern
methicillin
resist
acquisit
overal
analys
core
genom
mrsa
strain
suggest
rel
methicillinresist
clone
dispers
wide
across
globe
robinson
enright
analys
accessori
genom
mrsa
suggest
new
strain
emerg
local
via
frequent
de
novo
transfer
sccmec
element
word
appear
clonal
expans
rel
core
genom
accessori
genom
frequent
goe
genespecif
sweep
illustr
lina
et
al
appli
mlst
core
genom
sccmec
element
found
associ
clonal
complex
background
sccmec
element
sequenc
type
author
therefor
conclud
sccmec
appear
transfer
repeatedli
across
distinct
clonal
complex
particularli
case
sccmec
iv
repeatedli
within
clonal
complex
suggest
sccmec
spread
genespecif
sweep
chua
et
al
show
anoth
studi
mrsa
geograph
genet
distant
isol
ie
distantli
relat
core
genom
nevertheless
rel
conserv
accessori
element
includ
sccmec
type
iv
chua
et
al
suggest
transfer
happen
often
sweep
genespecif
anoth
exampl
studi
et
al
author
use
improv
sequenc
type
method
core
accessori
genom
investig
genet
relationship
within
singl
clonal
lineag
belong
clonal
complex
use
isol
across
countri
six
contin
contrast
lower
resolut
studi
came
analys
core
genom
sequenc
found
geographicallyassoci
phylogenet
clade
within
clonal
lineag
addit
analys
sccmec
sequenc
reveal
least
independ
transfer
sccmec
occur
clonal
group
alon
acquisit
appear
occur
local
rather
singl
acquisit
dissemin
global
fig
could
refer
case
multipl
origin
adapt
sccmec
element
soft
genespecif
sweep
pen
hermisson
author
estim
previou
calcul
rate
sccmec
acquisit
least
order
magnitud
low
taken
togeth
know
genet
divers
core
genom
nevertheless
contain
close
relat
resist
allel
frequent
transfer
occur
even
within
clonal
lineag
make
understand
evolutionari
histori
allel
complic
allel
transmit
independ
clonal
expans
core
genom
lineag
nevertheless
studi
drug
resist
aureu
illustr
research
achiev
fine
resolut
demograph
adapt
histori
aureu
use
improv
sequenc
technolog
case
facilit
explor
core
accessori
genom
research
begin
use
wholegenom
sequenc
aureu
even
finer
resolut
evolutionari
histori
mrsa
outbreak
possibl
exampl
holden
et
al
abl
pinpoint
popul
size
chang
geograph
origin
specif
clone
harri
et
al
abl
construct
transmiss
pathway
hospit
outbreak
staff
patient
thu
grow
avail
sequenc
data
wholegenom
sequenc
technolog
provid
abil
determin
resist
may
gener
unconstrain
global
transmiss
dynam
instead
track
local
spatial
scale
present
research
opportun
use
sequenc
tool
monitor
transmiss
network
within
hospit
limit
number
hospitalacquir
drugresist
infect
overal
transmiss
repeat
evolut
drug
resist
bacteri
popul
capabl
hgt
present
import
interest
problem
reconstruct
popul
structur
spatial
distribut
resist
cost
drugresist
pathogen
impos
human
health
enorm
high
make
tool
lead
increas
understand
evolut
spread
drug
resist
great
potenti
valu
therefor
import
tool
field
evolutionari
genet
includ
popul
genet
phylogenet
one
appli
pathogen
popul
tool
could
provid
meaning
insight
addit
possibl
help
prevent
evolut
spread
drug
resist
valuabl
lesson
learn
deepen
understand
evolutionari
biolog
make
pathogen
attract
studi
organ
review
highlight
five
evolutionari
genet
studi
pathogen
hope
give
sampl
rang
biolog
lesson
learn
studi
drug
resist
pathogen
first
show
classic
popul
genet
method
find
select
sweep
use
success
identifi
region
involv
resist
artemisinin
malaria
parasit
plasmodium
falciparum
next
describ
phylogenet
method
help
uncov
role
epistasi
evolut
influenza
surfac
protein
gener
evolut
oseltamivir
resist
particular
third
exampl
highlight
import
sgv
evolut
resist
antiretrovir
patient
hiv
fourth
show
drug
resist
mutat
use
explor
dynam
clonal
interfer
within
patient
infect
mycobacterium
tuberculosi
final
discuss
complic
involv
studi
bacteri
popul
horizont
gene
transfer
genet
element
contribut
spread
antibiot
resist
staphylococcu
aureu
five
exampl
meant
exhaust
rather
show
wealth
possibl
studi
organ
evolutionari
question
address
hope
five
exampl
convinc
reader
evolutionari
genet
drug
resist
appeal
field
case
highlight
studi
drug
resist
use
expand
understand
basic
evolutionari
process
insight
gain
exampl
limit
organ
mention
review
discoveri
made
way
depend
organ
biolog
avail
data
exampl
work
epistasi
influenza
possibl
extens
sequenc
collect
continu
happen
around
world
work
map
resist
allel
malaria
parasit
p
falciparum
also
depend
avail
data
addit
possibl
p
falciparum
high
recombin
rate
facilit
linkagebas
analys
describ
studi
sgv
hiv
possibl
relev
mutat
known
evolut
resist
happen
independ
everi
patient
give
research
abil
work
replic
evolutionari
histori
work
tuberculosi
possibl
resist
mutat
well
known
haplotyp
could
reconstruct
allel
frequenc
due
lack
recombin
final
exampl
drug
resist
evolut
mrsa
show
horizont
gene
transfer
studi
extens
multilocu
genotyp
data
avail
isol
collect
across
globe
similar
analys
perform
pathogen
exampl
highlight
work
select
sweep
p
falciparum
select
sweep
hitchhik
also
studi
hiv
zanini
neher
pen
et
al
feder
et
al
hepat
c
viru
bull
et
al
influenza
koell
et
al
strelkowa
use
mrsa
exampl
import
horizont
gene
transfer
mani
exampl
exampl
recent
studi
pneumococcu
describ
horizont
gene
transfer
soft
select
sweep
relat
drug
resist
vaccin
escap
croucher
et
al
anoth
exampl
group
pathogen
evolut
drug
resist
studi
herp
virus
cytomegaloviru
cmv
herp
viru
drug
resist
best
studi
mani
resist
mutat
known
hakki
chou
popul
geneticist
recent
start
analys
cmv
sequenc
renzett
et
al
drug
resist
also
evolv
herp
virus
varicellazost
viru
herp
simplex
viru
piret
boivin
brunnemann
et
al
virus
extens
analys
use
popul
genet
evolutionari
genet
method
case
role
evolutionari
genet
connect
inform
contain
genom
sequenc
process
underli
pathogen
evolut
requir
care
attent
divers
biolog
properti
pathogen
discuss
review
see
box
pathogen
evolut
repres
enorm
opportun
popul
geneticist
studi
major
question
evolutionari
biolog
also
contribut
understand
import
issu
public
health
combin
innov
popul
genet
approach
appropri
data
collect
hope
futur
studi
make
benefici
contribut
field
evolutionari
biolog
public
health
field
popul
genet
tradit
lean
heavili
use
fruit
fli
yeast
escherichia
coli
human
model
organ
howev
becom
clear
mani
pathogen
also
excel
model
system
pathogen
evolut
model
evolutionari
system
mani
advantag
pathogen
receiv
lot
attent
biomed
research
consequ
well
studi
extens
sampl
pathogen
alreadi
function
model
organ
lab
eg
influenza
foll
et
al
hiv
van
opijnen
berkhout
polio
acevedo
et
al
e
coli
toprak
et
al
allow
research
assess
characterist
popul
genet
epidemiolog
relev
laboratori
popul
exampl
cell
surfac
express
assay
perform
previous
mention
studi
oseltamivir
resist
influenza
pathogen
system
research
also
appli
known
select
pressur
precis
laboratori
environ
thu
allow
highresolut
measur
organ
respons
select
addit
pathogen
evolv
drug
resist
quickli
repeatedli
within
patient
case
mani
replic
evolutionari
histori
studi
hiv
hcv
tb
etc
pathogen
also
among
organ
genet
sequenc
data
avail
popul
genet
analysi
aureu
sequenc
influenza
sequenc
hiv
sequenc
malaria
sequenc
releas
genbank
alon
benson
et
al
access
may
moreov
decreas
cost
nextgener
sequenc
make
amount
new
data
pathogen
increas
exponenti
throughout
review
highlight
use
sequenc
data
popul
genet
theori
studi
pathogen
evolutionari
model
system
believ
pathogen
evolut
continu
fruit
area
research
evolutionari
biologist
fundament
insight
lead
benefici
public
health
consequ
sequenc
data
emerg
forese
futur
specif
question
would
like
see
address
intersect
popul
genet
drug
resist
pathogen
first
expect
work
bridg
withinv
betweenhost
dynam
eg
lythgo
fraser
import
consider
genet
variat
creat
select
within
host
howev
withinhost
process
shortliv
infect
yet
receiv
suffici
attent
expect
withinhost
work
includ
time
seri
deep
sampl
pathogen
tradit
studi
betweenhost
level
tuberculosi
work
describ
review
good
exampl
new
withinpati
work
influenza
also
done
roger
et
al
second
deeper
sampl
time
seri
becom
increasingli
possibl
estim
select
pressur
pathogen
estim
epistat
interact
mutat
work
method
current
use
identifi
mutat
evalu
select
virus
grown
cell
cultur
lou
et
al
foll
et
al
hope
find
use
clinic
sampl
taken
infect
patient
extend
method
patient
data
potenti
give
research
abil
studi
evolutionari
dynam
pathogen
within
patient
entir
cours
infect
anoth
import
goal
evolutionari
studi
pathogen
increas
predict
power
pathogen
evolut
recent
predict
evolut
seem
like
scienc
fiction
recent
work
chang
percept
possibl
addit
predict
phylogenet
methodolog
mention
discuss
epistasi
influenza
method
use
shape
protein
phylogeni
predict
evolutionari
trajectori
evalu
use
influenza
data
neher
et
al
work
show
predict
low
evolut
occur
big
step
much
higher
evolut
proce
small
step
neher
et
al
although
tend
fix
attent
larg
adapt
event
drug
resist
immun
escap
evolut
small
step
may
common
previous
expect
bhatt
et
al
strelkowa
gong
et
al
organ
like
influenza
new
vaccin
manufactur
everi
year
applic
new
predict
methodolog
use
popul
genet
theori
luksza
potenti
groundbreak
hope
work
drug
resist
review
offer
glimps
grow
field
intersect
studi
pathogen
evolut
evolutionari
genet
also
hope
illustr
field
studi
benefit
greatli
review
contribut
excit
futur
field
phylogenet
tree
neuraminidas
na
subtyp
illustr
role
permiss
mutat
tree
made
phyml
guindon
et
al
base
data
bloom
et
al
plot
use
ggtree
yu
lam
phylogeni
suggest
epistat
interact
mutat
base
maximumlikelihood
reconstruct
branch
resist
mutat
colour
red
wherea
without
colour
grey
nonresist
branch
mutat
colour
light
blue
nonresist
branch
mutat
colour
dark
blue
clade
mutat
nearli
fix
shade
blue
phylogeni
consist
idea
substitut
site
act
permiss
mutat
amelior
fit
cost
previou
background
allow
spread
branch
length
scale
given
unit
substitut
per
site
wilson
et
al
page
mol
ecol
author
manuscript
avail
pmc
januari
phylogenet
tree
neuraminidas
na
subtyp
illustr
put
epistat
interact
tree
fig
use
illustr
methodolog
present
kryazhimskiy
et
al
nonresist
branch
mutat
colour
blue
branch
resist
mutat
colour
red
phylogeni
suggest
epistat
interact
site
substitut
site
site
number
scheme
appear
multipl
time
immedi
follow
substitut
site
shade
blue
cooccurr
consist
idea
substitut
site
act
permiss
mutat
mutat
interact
posit
epistat
manner
determin
amount
drug
resist
stand
genet
variat
sgv
use
two
studi
two
differ
studi
percentag
patient
acquir
drug
resist
partit
whose
hiv
popul
acquir
drug
resist
sgv
light
blue
whose
popul
acquir
drug
resist
via
de
novo
mutat
dark
blue
total
rate
failur
higher
pared
studi
margot
studi
percentag
attribut
sgv
similar
two
studi
calcul
percentag
patient
fail
sgv
pared
et
al
studi
shown
inset
patient
partit
start
without
drugresist
sgv
left
drugresist
sgv
right
eleven
patient
expect
fail
due
de
novo
mutat
base
sampl
size
patient
remain
failur
attribut
failur
due
drug
resist
sgv
clonal
interfer
mycobacterium
tuberculosi
dynam
clonal
interfer
among
drug
resist
mutat
star
mutat
known
drug
resist
mutat
dot
aris
within
patient
tuberculosi
expand
colour
block
repres
tuberculosi
lineag
start
one
mutat
spread
popul
lineag
colour
depend
whether
mutat
possess
ultim
fix
popul
green
lost
blue
lineag
begin
mutat
known
drug
resist
mutat
nondrm
colour
brown
background
new
lineag
emerg
overlap
start
point
colour
block
trajectori
infer
allel
frequenc
point
sampl
black
vertic
line
mutat
infer
trajectori
close
match
clonal
dynam
mark
red
data
eldholm
et
al
size
circl
proport
haplotyp
frequenc
line
length
proport
number
mutat
step
haplotyp
panel
haplotyp
paint
colour
proport
countri
origin
isol
haplotyp
found
fourteen
lineag
label
n
tend
cluster
geograph
origin
emerg
suggest
specif
haplotyp
core
genom
aureu
clone
larg
endem
geograph
area
panel
b
minimumspan
tree
use
haplotyp
paint
colour
proport
sccmec
element
type
cooccur
isol
sccmec
element
nontyp
nt
like
due
novel
variant
parsimoni
distribut
acquisit
event
sccmec
indic
roman
numer
place
along
branch
tree
roman
numer
correspond
sccmec
type
although
actual
number
sccmec
acquisit
may
higher
note
differ
sccmec
type
present
across
globe
acquisit
event
tend
occur
tip
tree
suggest
methicillin
resist
tend
evolv
within
local
aureu
strain
oppos
occur
dissemin
global
